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This article is part of a series on overdiagnosis looking at the risks and
harms to patients of expanding definitions of disease and increasing
use of new diagnostic technologies
Many patients report sadness or distress during consultations
with primary care doctors. Such emotions may be related to
grief and other life stresses, including the stress of physical
illness. Sometimes sadness appears out of the blue, without
obvious relation to external causes. Over recent decades there
has been an increasing tendency, especially in primary care, to
diagnose depression (commonly major depressive disorder) in
patients presenting with sadness or distress and offer them
antidepressant medication.1-3
In this paper we offer a critical review of the diagnosis of major
depressive disorder, show how and why this broad diagnostic
label has resulted in overdiagnosis and overtreatment, and
suggest how the approach to diagnosis and management of
depression should change to reduce stigmatising the sad and
provide better help for those who most need vigilant care and
medical treatment.
Evolving views of what constitutes
depression
Descriptions of depression can be found in the Bible and
Shakespeare, but no formal definition existed until the third
version of the American Psychiatric Association’s classification
systems for mental disorders was published in 1980 (DSM-III).
The manual set out clear operational criteria to aid clinicians in
diagnosing mental disorders (see box 1) and introduced the term
major depressive disorder.
Since thenmajor depressive disorder has receivedmore research
attention than any other diagnosis in psychiatry but has created
many problems. The criteria, which have not changed since
1980, capture too heterogeneous a population for research
studies and are so loose that, in everyday clinical practice,
ordinary sadness can be easily confused with clinical
depression.5
Unhelpful classifications of mental
disorders
Under DSM-III the term major depressive disorder combined
what had formerly been described as
“melancholia”—characterised by severe, disabling, and
sometimes life threatening depression, often coming out of the
blue and characterised by marked diurnal variation, suicidal
thoughts, and somatic symptoms—with “reactive depression.”
Reactive depression contrasted in almost every way with
melancholia, with onset closely linked to a definable life event
and with symptoms that were milder and typically including
sadness, loss of interest, and feelings of guilt and unworthiness.
Somatic changes, including difficulty sleeping and loss of
appetite, were less profound and enduring in reactive depression
than in melancholia. Those affected retained the capacity to feel
pleasure. Symptoms were usually least troubling in the morning
and patients tended to get better over time and respond well to
placebo and psychotherapy. Thosewithmelancholia, by contrast,
were more likely to have disturbed sleep and abnormal
dexamethasone suppression test results6 7 and to respond to drug
treatment or electroconvulsive therapy.8
Although the DSM-III definition of major depressive disorder
was meant to provide simplicity and increase reliability of
diagnosis, from the beginning it was recognised that it would
capture a heterogeneous population of patients. The definition
therefore provided severity ratings and different subtypes (box
1). Unfortunately, however, the valuable distinctions offered
by severity and subtype ratings were generally ignored in both
clinical practice and research.9Major depressive disorder became
homogenised to include “mild” major depression—arguably a
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Summary box
Clinical context—Diagnoses of major depressive disorder and treatment with antidepressant drugs are increasing
Diagnostic change—DSM-III homogenised the diagnosis of depression and the newDSM-5 classification broadens the definition further,
allowing the diagnosis of major depressive disorder just two weeks after bereavement
Rationale for change—To provide more patients with access to effective treatments
Leap of faith—Accurate diagnosis of mild depression is possible; treatment is necessary and leads to better outcomes
Increase in disease—Although community prevalence of major depressive disorder has remained static, diagnoses doubled among
Medicare recipients in the US between 1992-95 and 2002-05
Evidence of overdiagnosis—Depression is nowmore likely to be overdiagnosed than underdiagnosed in primary care. Rates of prescribing
of antidepressant medication doubled in the UK between 1998 and 2010 and in the US 11% of the population aged over 11 now takes
an antidepressant. People without evidence of major depressive disorder are being prescribed drug treatment
Harms from overdiagnosis—Turning grief and other life stresses into mental disorders represents medical intrusion on personal emotions.
It adds unnecessary medication and costs, and distracts attention and resources from those who really need them
Limitations—We do not know whether clinicians will follow the DSM-5 proposals
Conclusions—Patients with mild depression or uncomplicated grief reaction usually have a good prognosis and don’t need drug treatment.
Clinicians should focus on identifying people with moderate to severe depressions and sufficient impairment to require treatment.
Box 1: Diagnostic classification of mental disorders
Diagnostic and Statistical Manual of Mental Disorders (DSM) III (1980) introduced a unitary diagnosis of major depressive disorder (MDD)
with nine symptoms (mood, interest, activity, fatigue, weight/appetite, sleep, guilt, concentration, and suicidality).
The main emphasis of DSM-III was on severity ratings:
• Mild MDD was defined as five or six symptoms of mild severity, including either low mood or loss of interest
• Moderate MDD was defined as seven to eight symptoms with moderate impairment
• Severe MDD was defined as six or more symptoms with severe impairment or psychotic features and strong suicidal intent
DSM III also included depressive subtypes:
• Secondary depression arose from a clear external cause
• Psychotic depression had associated psychotic symptoms
• Melancholic depression involved lack of pleasure or lack of mood reactivity plus three of the following: subjective mood qualitatively
different from grief or loss; severe loss of appetite or weight; psychomotor agitation or retardation; early morning waking, excessive
guilt; and mood worse in the morning.
DSM-IV (1994) used a similar classification system.4 DSM-5 (2013) now allows grief reaction to be classified as major depressive disorder
(MDD) after two weeks.
The International Statistical Classification of Diseases and Related Health Problems (ICD), produced by the World Health Organization, also
includes criteria for mental disorders. This is used more widely in Europe and other parts of the world. The coding systems of DSM and ICD
are designed to correspond with each other
contradiction in terms for it is not major, nor really depressive
or a disorder.
DSM-IIIR and DSM-IV carried forward the DSM-III definition,
and the recently published DSM-5 broadens the diagnosis of
major depressive disorder still further. It allowsmajor depressive
disorder to be diagnosed just two weeks after a bereavement.
The change in the diagnostic status of grief from bereavement
(not a mental illness) to depressive episode (a mental illness)
introduced by DSM-5 was designed to provide more patients
with access to effective treatments.10 This is particularly relevant
in insurance based health systems such as the US, where a
specific diagnosis is needed before funders will agree to pay
the costs of treatment. It has, however, provoked both
controversy and concern focused on the medicalisation of the
normal human experiences of loss.5 11 12
Homogenisation of depression has been
a mistake
People with uncomplicated episodes of major depressive
disorder (lasting no longer than two months and not including
suicidal ideation, psychotic ideation, psychomotor retardation,
or feelings of worthlessness) are hardly more likely to have a
further episode within 12 months than people with no history
of major depressive disorder (3.7% v 3.0%).13 These episodes,
along with mild and non-melancholic episodes, may be better
understood as normal intense sadness.13 An Australian primary
care study of 789 patients with depressive disorders found four
different trajectories: most patients (n=532) had amild and static
symptom trajectory, very different from the experience of the
small minority of people (n=69) with severe persistent
depression, who had high levels of disadvantage, abuse,
morbidity, and disability.14
Including people, as the DSM- 5 classification does, who are
experiencing grief only two weeks after the loss of a loved one
is a mistake. Bereaved people follow a course very different
from those with recurrent major depressive disorder. A study
of over 30 000 US citizens found that single bereavement related
brief depressive episodes have distinct demographic and
symptom profiles that differ from those of other types of
depressive episodes and are not associated with increased risk
of future depression.15 Uncomplicated bereavement is not
associated with an increase in suicidality.16
Increase in diagnosis of depression and
antidepressant drug prescriptions
The prevalence of depressive disorders in the community is
stable. In the United States two national comorbidity surveys a
decade apart found prevalences of major depressive disorder of
6.1% and 6.6%.17 18 In England the one week prevalence of
depressive episodes among adults decreased from 2.6% in 2000
to 2.3% in 2007.19 20
Meanwhile rates of diagnosis have increased considerably.
Although community surveys that use lay interviewers have
shown little change in prevalence over time, diagnoses of
depression among Medicare beneficiaries doubled between
1992-95 and 2002-05.1This is not because primary care doctors
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are getting better at identifying major depressive disorder;
overdiagnosis is now more common than underdiagnosis. A
meta-analysis of 41 studies, including 50 371 patients, estimated
that for every 100 unselected cases seen in primary care, there
were more false positive cases (n=15) than either missed (n=10)
or identified cases (n=10) of depressive disorder as judged by
standard diagnostic criteria.2 In a study of 5639 participants
from the 2009-2010 US National Survey of Drug Use and
Health, clinician identified depression was compared with
assessments for major depressive episodes using a structured
interview. Only 38% of adults (including only 9% of those aged
65 and over) with clinician identified depression met diagnostic
criteria for depression during the previous year; nevertheless,
most participants were taking psychiatric drugs.21 The trend to
overdiagnosis may increase as DSM-5 diagnostic criteria loosen.
Rates of prescribing of antidepressants to patients having no
evidence of major depressive disorder, or fewer symptoms than
DSM would advise, are also increasing in primary care. The
proportion of visits to non-psychiatrists at which antidepressants
were prescribed but no psychiatric diagnoses were noted
increased in the US from 60% to 73% between 1996 and 2007.22
About 11% of the US population aged over 11 now take an
antidepressant, including 23% of women in their 40s and 50s.3
In England, antidepressant prescribing increased at over 10%
each year between 1998 and 2010,23 a rise far greater than for
any other psychiatric medication. This is explained mainly by
an increase in long term prescriptions.24 Similar rises have been
described in other Western nations including Australia,25
Canada,26 and Denmark.27
Drivers of overdiagnosis
The homogenisation of major depressive disorder has been in
part a consequence of heavy drug company marketing and an
overstrong focus among many psychiatrists on the biological
correlates of psychiatric symptoms rather than the psychological,
social, and cultural.28 The rate of diagnosis of depression has
increased substantially since the development and marketing
of selective serotonin reuptake inhibitors,29 a trend assisted by
drug companies’ financial support for prominent academic
psychiatric units12 and direct to consumer advertising in the US.
General practitioners and the public are complicit in this. For
GPs a diagnosis of depression may be an attractive instrument
for managing uncertainty in the consulting room,30 especially
as its commonest treatment comes in the form of a once daily
pill and is encouraged by clinical guidelines and indicators.
Patients often request treatment for symptoms of sadness, and
doctors and patients can feel obliged to offer and accept a
diagnosis of major depressive disorder.31
In addition, there is a trend in Western societies to expect the
right to happiness and a need to restrict the range of negative
emotions that are considered “acceptable and normal.”32
Pharmaceutical companies and psychiatric nosologists derive
their positions on depression diagnoses from a set of common
but implicit value judgments.33
What the evidence shows
The weight of evidence from meta-analyses of placebo
controlled trials shows that antidepressant drugs have little or
no effect in mild depression.34-37Although there is some evidence
that the benefits of treatment compared with placebo are not
related to baseline severity,38 there are continued concerns about
publication bias in data provided by drug companies.39
The placebo effect of antidepressant drugs is substantial and
increasing, partly because less severely depressed people now
take part in drug trials.40 The role of regression to the mean in
assessing the effects of antidepressants is also important since
many people with reactive depression get better with time,
regardless of treatment. Watchful waiting can have a stronger
effect than antidepressants.41
There is no substantive evidence that people with uncomplicated
bereavement benefit from antidepressants, and a dearth of
clinical trial evidence of response to medication in those with
complicated grief reactions.13 Many conditions currently
diagnosed as major depressive disorder, especially those related
to other forms of loss, are better understood within a model of
grief that does not assume drug treatment.42
Harms from overdiagnosis
Turning grief and other responses to loss into a mental disorder
is a medical intrusion into private emotions.43 It substitutes a
superficial medical ritual for deep and time honoured cultural
ones and stigmatises the experience.33 It leads people to act
under the description of a psychiatric diagnosis, believing
themselves to be and behaving as if they are someone with a
mental illness and compromising their sense of agency.33 44 By
putting a simplistic time frame on recovery from grief, DSM-5
is stepping further away from the personal interaction that should
be the basis of healthcare.
These problems are greater in cross-cultural consultations with
patients for whom depression may be an alien concept. Recent
asylum seekers, for example, have often experienced severe and
traumatic losses. Subsuming the consequent distress within a
diagnosis of depressive disorder replaces loss with illness and
individualises previously social problems.45
Bringing grief within the category of major depressive disorder
adds unnecessary medication, with its inevitable side effects
and carries added risks including increased suicidal thinking in
children and young people.46 and risks of interaction with drugs
prescribed for other health problems.47 Unjustified use of
antidepressants increases the costs of healthcare. The excess
cost of care associated with prescribing antidepressants to older
Canadians without depression was estimated as $C1800 (£1000;
€1250; $1700) per person.48 An expanded focus on grief will
also affect existing psychiatric diagnosis, distracting attention
and resources from those who have severe mental health
problems.
How to do better
Diagnostic criteria should be tightened. Milder symptoms must
be persistent throughout the day, be present for at least a month
or two and cause significant distress or impairment before a
diagnosis of mild major depression is made. For moderate and
severe major depression, existing diagnostic criteria should be
accurately applied, so that diagnoses are made only in the
presence of substantive symptoms and clear associated
impairment. Patients presenting with milder or loss related
symptoms should not be dismissed, but more attention should
be given to benefits of time, support, advice, social networks,
and psychological interventions.49 There are opportunities to
avoid the mistakes of DSM-5 in ICD-11, which is now in
preparation.
GPs should focus on identifying patients with severe depression50
and provide themwith better access to adequate evidence based
care.51 These include two main groups of patients: those with
symptoms of melancholia and those with severe persistent
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symptoms associated with socioeconomic disadvantage and
disability (box 1).14
Drug companies should be stopped from marketing
antidepressant medication to physicians and the public and from
supporting professional organisations and consumer groups.
What to discuss with patients
High rates of placebo response account for much of the seeming
beneficial effects of medication and this should be discussed
sensitively with patients, who also need to be made aware of
the side effects, risks and costs associated with antidepressants.
Informing them of the way that drug companies have acted to
boost sales of their drugs may also be appropriate. There is still
a widely held view that all depression is “brain disease” caused
by chemical imbalance which can be “corrected” by pills, and
countering it is important by noting the relevance of life
circumstances.
Patients can be helped by listening carefully to their story,
promoting the value of time as a healer and encouraging them
to build resilience through exercise, support, and (where
possible) making changes to their circumstances in dealing with
everyday life problems.52 A diagnosis of depression may not be
necessary (box 2). A shared approach to decision making is
essential. Patients should also be encouraged to share
experiences and learn from others through organisations such
as Healthtalkonline (www.healthtalkonline.org). Watchful
waiting over multiple visits can enable doctors to see if the
problems will resolve without intervention, an approach that
plays to the strengths of experienced primary care doctors.
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Box 2: Is my patient really depressed?
• Before diagnosing depression, listen carefully to the patient’s story and consider the context:
Has the patient experienced grief or other life problems?
Are symptoms mild and recent?
Is this a first episode?
• Mild symptoms, or symptoms related to grief or other life problems, usually do not become more severe over time and a diagnosis of
depression should be avoided whenever possible
• Patients with mild depressive symptoms don’t need antidepressants—any benefit is likely to be due to the high placebo effect
• Mild symptoms, or symptoms related to grief or life problems, are likely to resolve with time, psychological support, and environmental
manipulation
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